FDA Flags Lower Efficacy For Merck's Keytruda, Roche's Tecentriq In Frontline Bladder Cancer Trials
In patients with previously untreated metastatic bladder cancer with low PD-L1 expression, PD-1 drugs alone don't work as well as chemo.
You may also be interested in...
The CheckMate-901 trial failed on one of its primary endpoints, but the company will continue the trial to explore additional primary endpoints.
Keeping track of US FDA approvals last week included watching the creative and the familiar.
The failure earlier this week of Roche's Tecentriq in second line bladder cancer left both the company and analysts surprised. Bladder cancer is a competitive space with a number of other immune-oncology products at or close to market. What does the Tecentriq result mean for them?